Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females

• ClinicalTrials.gov Identifier: NCT02740777
• Recruitment Status: Completed
• First Posted: April 15, 2016
• Last Update Posted: April 13, 2023
• Sponsor: Shanghai Zerun Biotechnology Co.,Ltd
• Collaborator: Guangxi Center for Disease Control and Prevention
• Information provided by (Responsible Party): Shanghai Zerun Biotechnology Co.,Ltd

Study Description

Brief Summary:

To evaluate the immune non-inferiority, as measured by antibody responses, of a 2-dose immunization schedule (0, 6 months) of recombinant human papillomavirus virus-like particle vaccine (type 16 and 18 L1 proteins, yeast) (hereinafter referred as HPV-2 vaccine) in adolescent females aged 9 to 14 years in comparison to 3-dose immunization schedule (0, 2, 6 months) in young females aged 18 to 26 years.

Condition or disease	Intervention/treatment	Phase
Human Papillomavirus; Cervical Intraepithelial Neoplasia; Persistent Infection	Biological: HPV-16/18 vaccine	Phase 2

Detailed Description:

The study plans to enroll 600 adolescent females aged 9 to 14 years and 300 adult females aged 18 to 26 years. The adolescents will be divided into two cohorts, 300 each, receiving either a 2-dose (0, 6 months) immunization schedule or a 3-dose (0, 2, 6 months) immunization schedule. The adult female group will receive a 3-dose (0, 2, 6 months) immunization schedule.

Each subject shall be administrated with the studied vaccine according to either 2-dose or 3-dose schedule as above. Immediate reactions occurred during 30 minutes after each inoculation, all the local and systematic reactions occurred from 0 to 7 days after each inoculation will be recorded. All the adverse events (AEs) occurred from the first dose of administration to 1 month after the final dose of administration, as well as all the serious adverse events (SAEs) occurred from the first dose of administration to 6 months after the final dose of administration will be collected. Blood samples will be collected at day 0 (prior to immunization) , month 6 (prior to the last injection) , month 7, month 12, month 24, and month 36. All the blood samples will be tested HPV 16- and HPV 18-specific antibody titers.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 900 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Prevention
• Official Title: Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years
• Actual Study Start Date: February 2016
• Actual Primary Completion Date: November 2016
• Actual Study Completion Date: July 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: 2-dose adolescent; 300 adolescent girl will receive a two-dose schedule (0 day, 6 months) immunization of HPV-16/18 vaccine.	Biological: HPV-16/18 vaccine; HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
Experimental: 3-dose adolescent; 300 adolescent girl will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.	Biological: HPV-16/18 vaccine; HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
Experimental: 3-dose adult; 300 adult women will receive a three-dose schedule (0 day, 2 months, 6 months) immunization of HPV-16/18 vaccine.	Biological: HPV-16/18 vaccine; HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.

Outcome Measures

Primary Outcome Measures :

1. HPV-16 and HPV-18 antibody titers (GMT) [ Time Frame: one month after the final injection ]
   Compare the HPV-16 and HPV-18 specific antibody titers (GMT) between the 2-dose immunization schedule (0, 6 months) in adolescent females aged 9 to 14 years and the 3-dose immunization schedule (0, 2, 6 months) in young females aged 18 to 26 years.

Secondary Outcome Measures :

1. HPV-16 and HPV-18 antibody titers (GMT) and the seroconversion rate [ Time Frame: 30 months after the final injection ]
   Compare the immunogenicity between the 2-dose (0, 6 months) and the 3-dose (0, 2, 6 months) immunization schedules in adolescent females aged 9-14 years, on the basis of: 1) antibody titers (GMT) and the seroconversion rate at one month after the final injection, 2) antibody titer persistence and 3) antibody titers at a steady status.
2. Local and systemic adverse events (AEs) [ Time Frame: 6 months after the final injection ]
   Evaluate all local and systemic adverse events (AEs) occurred within 7 days after each inoculation, at one month and 6 month after the whole immunization

Eligibility Criteria

• Ages Eligible for Study: 9 Years to 24 Years (Child, Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

Adult group:

• 18-26 healthy female
• enable to provide an legal identification
• have the ability to understand and sign the Informed Consent Form
• aren't pregnant and do not have pregnancy plan within the 7 months after the first injection
• used effective contraceptive method from the last menstruation, and agreed to avoid sexual activity without effective contraceptive method within the 15 days after injection

Adolescent group:

• 9-14 healthy female
• enable to provide an legal identification
• guardians have the ability to understand the Informed Consent Form, and both participant and guardian agreed to sign the Form (in case of unable to sign, the participant can use fingerprint as signature)

Exclusion Criteria:

• History of HPV infection
• Previous administration of any HPV vaccine
• History of severe allergic reaction requiring medical intervention (such as oral and throat swelling, difficulty breathing, hypotension or shock)
• History of allergic to vaccine, or to any ingredient of vaccine.
• History of epilepsy, seizures or convulsions, or family history of mental illness
• Subjects are immunocompromised or have been diagnosed as suffering from congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation (JRA), inflammatory bowel disease or other autoimmune diseases, administration of immunosuppressants with six months prior to the first vaccine dose.
• History of asthma, thyroidectomy, angioneurotic edema, diabetes or malignant
• Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy
• Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency, coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder
• Acute disease or chronic disease acute exacerbation 7 days prior to vaccination
• Administration of immunoglobulins and/or any blood products within 3 months, or administration of any live attenuated vaccine within 28 days, or administration of any subunit or inactivated vaccines within 14 days.
• Fever or axillary temperature> 37.0 °C before vaccination
• During menstrual period, breastfeeding, pregnancy(pregnancy test positive), or planned pregnant within 7 month
• History of hypertension, physical examination systolic blood pressure> 150mmHg and/or diastolic blood pressure> 100mmHg
• Abnormal laboratory tests parameters
• Any clinical significant disease or findings during study screening that, in the opinion of the Investigator may interfere with the study

Contacts and Locations

Locations

China, Guangxi

Hezhou Center for Disease Prevention and Control

Hezhou, Guangxi, China, 542899

Zhongshan Center for Disease Prevention and Control

Zhongshan, Guangxi, China, 542699

Sponsors and Collaborators

Shanghai Zerun Biotechnology Co.,Ltd

Guangxi Center for Disease Control and Prevention

Investigators

• Principal Investigator: Zhaojun Mo; Guangxi Center for Disease Prevention and Control(GXCDC)

More Information

• Responsible Party: Shanghai Zerun Biotechnology Co.,Ltd
• ClinicalTrials.gov Identifier: NCT02740777
• Other Study ID Numbers: 311-HPV-1004
• First Posted: April 15, 2016
• Last Update Posted: April 13, 2023
• Last Verified: April 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Additional relevant MeSH terms:

Persistent Infection; Uterine Cervical Dysplasia; Neoplasms; Precancerous Conditions; Uterine Cervical Diseases; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Infections; Disease Attributes; Pathologic Processes